In PTEN-negative PC3 prostate cancer cells, 40–120 μM fisetin for 48 h reduced recovered mTOR activity and cellular phospho-Akt (S473). ATP levels also declined, limiting interpretation of these responses as selective pathway inhibition. [2]
In etoposide-treated IMR90 fibroblasts, 48 h fisetin exposure reduced viable SA-β-gal-positive cell counts at 7.5 and 15 μM relative to DMSO controls. This marker-based result alone does not establish selective killing of senescent cells. [3]
Cell-free kinase activity profiling
Biochemical assay · Cell-free mTOR, mTOR + FKBP12, p70S6K and AKT1 kinase assays [1]
Fisetin inhibited the four assayed kinase conditions. The reported IC50 values describe this radiometric assay and are not treatment doses or a kinome-wide selectivity profile.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10-dose IC50 series, 3-fold serial dilution starting at 100 μM fisetin
- Exposure duration
- 2 h at room temperature
- Method
- Radiometric kinase activity assay at Reaction Biology Corporation; 30 μM ATP; phosphorylation products captured on P81 filters.
- Vehicle
- DMSO; reaction buffer contains 1% DMSO
- Co-treatment
- mTOR tested with and without FKBP12. Rapamycin and staurosporine tested separately as reference inhibitors.
- Reported limits
- Independent replicate number and uncertainty for fitted IC50 values are not specified in the acquired kinase-activity description.
Methods and source locations
Compound reported in the paper: Fisetin
Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.
Materials; Kinase activity assays; Results, kinase-activity subsection; Figure 8A–E
mTOR catalytic activity without FKBP12: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A–B; Kinase activity assays
mTOR catalytic activity with FKBP12: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,C; Kinase activity assays
p70S6K catalytic activity: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,D; Kinase activity assays
AKT1 catalytic activity: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,E; Kinase activity assays
mTOR/Akt pathway response in PC3 cells
Cell-based study · Androgen-independent, PTEN-negative human PC3 prostate cancer cells [2]
A 48 h exposure to fisetin reduced mTOR activity recovered from treated cells and phospho-Akt (S473). Cellular ATP also decreased. These cellular responses do not establish selective, direct enzyme inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 40, 80 and 120 μM
- Exposure duration
- 48 h
- Method
- Cell exposure followed by immunoprecipitated mTOR activity assay, phospho-Akt ELISA and cellular ATP assay.
- Reported limits
- The solvent and solvent fraction for the adopted Figures 1–2 exposure are not explicitly established in the read assay text; DMSO in the separate colony assay is not transferred here. Figures identify a 0 μM control.
Methods and source locations
Compound reported in the paper: Fisetin
Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.
Reagents and cell culture; mTOR kinase assay; Phospho-Akt ELISA; Measurement of ATP; Results for Figures 1D and 2C,E; Figures 1–2 captions
Activity of mTOR immunoprecipitated from fisetin-treated cells: K-LISA mTOR assay using S6K70 substrate; mean ± SEM, three independent experiments (caption) — Results, first subsection; Figure 1D and caption; mTOR kinase assay
Cellular phospho-Akt (S473) level: PathScan phospho-Akt (S473) ELISA; caption describes representative results of three independent experiments, mean ± SEM — Results, mTORC1/2 and Akt subsection; Figure 2C and caption; Phospho-Akt ELISA
Cellular ATP level: ATP bioluminescence assay; mean ± SEM, three independent experiments (caption) — Results, TSC2/Akt/AMPK subsection; Figure 2E and caption; Measurement of ATP
Senescence-associated cell counts in IMR90 fibroblasts
Cell-based study · Human IMR90 fibroblasts after etoposide-induced senescence [3]
Fisetin reduced the relative number of viable SA-β-gal-positive cells at 7.5 and 15 μM compared with DMSO controls. Total viable-cell counts were measured in parallel. This assay does not by itself distinguish senolysis from a change in senescence-marker expression.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3.75, 7.5 and 15 μM (Figure 1C); vehicle control
- Exposure duration
- 48 h fisetin exposure
- Method
- IMR90 cells received 20 μM etoposide for 24 h; two days after its removal, approximately 70% were SA-β-gal positive. C12FDG imaging quantified SA-β-gal-positive cells and Hoechst imaging total viable cells.
- Vehicle
- DMSO; fraction not specified
- Co-treatment
- Sequential etoposide induction followed by fisetin; no concurrent etoposide combination claim.
- Reported limits
- Number of independent biological replicates for IMR90 is not clearly specified. Caption/methods refer to duplicate samples and 3–5 fields per well; Figure 1C wording states mean ± SD and the shared caption ends with mean ± SEM. No numerical error estimates adopted.
Methods and source locations
Compound reported in the paper: Fisetin
Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.
Materials and methods 2.1 and 2.4; Results first paragraph; Figure 1C and caption
Viable SA-β-gal-positive IMR90 cells relative to vehicle control: C12FDG fluorescence imaging; total viable cells measured in parallel; two-tailed unpaired Student’s t-test (caption) — Figure 1C and shared caption; Materials and methods 2.4